Project Grant R01EB037601
- Federal Project Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded the University of Pennsylvania a $616,897 Project Grant on August 8, 2025, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award, with a completion date of July 31, 2026, funds development of synthetic intracellular microcompartments designed to enhance immune cell function in immunotherapy applications....
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded the University of Pennsylvania a Project Grant totaling $406,250 under the Biomedical Research and Research Training program (CFDA 93.859) on March 2, 2026, with completion targeted for December 31, 2030. This five-year research initiative advances nucleic acid chemistry and in vitro selection (SELEX) techniques to expand the genetic toolkit for RNA silencing and editing applications. The...
- Federal Grant Award Summary The University of Pennsylvania received a $446,875 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded September 1, 2025, with completion scheduled for August 31, 2027. The project deliverables focus on developing deep learning tools to advance the diagnosis and prognosis of Metabolic...
- Federal Grant Award Summary The University of Pennsylvania received a $406,250 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026, through December 31, 2030. The award supports the development of correlated factor models and statistical methodologies for analyzing complex multimodal biomedical datasets. The project deliverables include: (1) model-based imputation...
- Federal Grant Award Summary The University of Pennsylvania received a $434,375 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with a completion date of July 31, 2027. This research project will investigate retroelement-mediated cis-regulation of embryonic hematopoiesis, specifically examining how retrotransposon-derived long terminal repeats function as...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pennsylvania a Project Grant of $1.14M under the Cardiovascular Diseases Research program (CFDA 93.837) to advance therapeutic gene-editing approaches for cardiovascular disease. Awarded on March 20, 2026, with completion targeted for January 31, 2033, this grant funds translational research building on the investigator's pioneering work in base editing therapeutics. The research will...
- Project Grant Award Summary The University of Pennsylvania received a $446,875 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 6, 2026 through December 31, 2030. This award funds a five-year research initiative investigating the mechanisms and roles of RNA editing and sensing in immune regulation. The research focuses on understanding how ADAR1-mediated...
- Federal Grant Award Summary The University of Pennsylvania received a $573,005 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) on May 15, 2026, with completion scheduled for May 14, 2027. The award funds the acquisition of a LUMICKS Avidion Cell Avidity Analyzer, a high-throughput platform designed to quantitatively measure cell-cell interaction avidity—a critical parameter for evaluating the...
- Federal Project Grant Summary The University of Pennsylvania received a $487,500 Project Grant award dated August 15, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research through July 31, 2030, focused on developing an in vivo CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screening platform to identify genetic regulators of microglial phagocytosis...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded the University of Pennsylvania a Project Grant of $653,230 on August 6, 2025, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The project, titled "Advancing Neurosymbolic AI for Smart and Trustworthy Healthcare," will develop MED-SCALLOP, a novel neurosymbolic artificial intelligence methodology and software...
The University of Pennsylvania received a $645,265 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), effective June 1, 2026 through February 28, 2030. This award supports the development and validation of DNA-loaded lipid nanoparticles (DNA-LNPs) as a therapeutic delivery platform for treating chronic diseases such as atherosclerosis and emphysema. Building on the clinical success of messenger RNA–lipid nanoparticle (mRNA-LNP) vaccines, the research addresses critical limitations of mRNA therapeutics—including short half-life and off-target expression—by loading lipid nanoparticles with DNA instead, which offers extended protein expression duration (~6 months in vivo) and accommodation of large plasmids exceeding 10 kilobases. The key innovation involves resolving the historical toxicity challenge of DNA-LNPs by incorporating nitrated lipid NOA, a naturally occurring inhibitor of the STING pathway, which eliminates the severe inflammatory response that previously resulted in 100% mortality in animal models. The funded research aims to establish DNA-LNPs as a viable vector technology capable of expressing any protein without the size constraints of alternative vectors such as adeno-associated viruses, thereby expanding therapeutic options for chronic disease treatment. The project is positioned to advance the field through the development, validation, and application of this bioengineering technology platform.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $645.3k | 5/27/26 |